MissionIR Articles
-
MissionIRNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Benefiting as Utilities Look to Reduce Dependence on Fossil Fuels
EverGen (TSX.V: EVGN) (OTCQX: EVGIF), a leading Canadian renewable energy company and Canada’s renewable natural gas (“RNG”) infrastructure platform, is among companies that are rising to the challenge to provide RNG solutions for utilities increasingly looking to slash pollution and reduce the world’s dependence on fossil fuels. “Climate change awareness has consumers, regulators and companies…
-
MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is focused on fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. “Silo Pharma is currently developing ketamine treatments for fibromyalgia – a chronic disease that causes pain throughout the…
-
MissionIRNewsBreaks – RYVYL Inc. (NASDAQ: RVYL) Announces Plans to Report Q3 2022 Financial Results
RYVYL (NASDAQ: RVYL), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation to conduct payment transactions, is planning to release its third quarter 2022 financial report this month. The company announced that it will release the report on Nov. 14, 2022. On the same day, RYVYL executives will host…
-
MissionIRNewsBreaks – Cepton Inc. (NASDAQ: CPTN) to Participate in 13th Craig-Hallum Alpha Select Conference
Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that its Chief Executive Officer Dr. Jun Pei and Chief Financial Officer Hull Xu will be participating in the 13th Craig-Hallum Alpha Select Conference. The event is slated to be held in New York City on Nov. 17, 2022. Cepton…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at the Jefferies London Healthcare Conference taking place on Nov. 15-17, 2022. Drysdale’s presentation is slated to begin at…
-
MissionIRNewsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Distinctive in Highly Competitive Online Gambling Space
Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, white labels its industry-leading GM-AG System that can be custom-built from 10,000+ game options for its roughly 650 clients serving about 6.8 million end users. “The online gambling space is highly competitive, leading to most of the world’s biggest…
-
MissionIRNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Eyes Steady Growth, Traction in Distinctive Solutions
Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has grown its operations with numerous improvements to its cloud-based marketplace that simplifies the once-complex process of international over-the-road (“OTR”) cross-border shipping. In addition, Fr8Tech is constantly exploring new ways to create value for its clients, streamline the region’s cross-border shipping process, and carry that over into respective domestic markets.…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin…
-
MissionIRNewsBreaks – Knightscope Inc. (NASDAQ: KSCP) Announces New Contracts, Indicative of Company’s Continued Reach
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced five new contracts. The contracts are with companies across the United States from several different industries. According to the announcement, the companies include an Ohio-based global pharmaceutical manufacturer and distributor of medical and laboratory products, as well as a provider of performance…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross…
-
MissionIRNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Secures LOI for up to $100M to Help Fund next Stage of Growth
Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer within high-performance lidar solutions, has rapidly emerged as a leader amongst its peers – deploying its unique capabilities across a host of different environments, ranging from traffic systems in Cape Town, South Africa, to airport terminal monitoring in the U.S. “Cepton’s long-term automotive Tier 1 partner,…
-
MissionIRNewsBreaks – Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Ideally Positioned as Cybersecurity Industry Surges
Cerberus Sentinel (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider based in Scottsdale, Arizona, is poised to profit as the cybersecurity industry prepares for rapid growth. A recent Cybersecurity Report published by McKinsey & Company highlighted this forecasted rise, citing a new survey revealing a $2 trillion market opportunity for cybersecurity…
-
MissionIRNewsBreaks – Eloro Resources Ltd.’s (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Drill Program Unearths Significant Proportions of Precious Metals
Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, recently released positive results from its fully financed drill program at its Iska Iska project in Bolivia. “Results from the company’s diamond drilling program – a process that…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Successful Results of Human Clinical Hypertension Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study, HYPER-H21-4, may be the first-ever study to indicate a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral cannabidiol (“CBD”) therapy. The study is evaluating Lexaria’s patented DehydraTECH(TM)-CBD capsule formulation. LEXX…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its EMBARK Psychedelic-Assisted Psychotherapy Training Program have announced the graduation of highly skilled facilitators who are now prepared to handle a range of experiences that participants of psychedelic-assisted psychotherapy may undergo. The training program includes foundational training enabling participants to…
-
MissionIRNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Stands Distinct from Others in Lidar Sector
Cepton (NASDAQ: CPTN), a world-leading lidar provider, remains committed to making a potentially game-changing technology available in everyday cars, not just luxury vehicles. “The company expects lidar to benefit more consumers as the technology gets rolled out to all cars, making autonomous driving safer for all. Cepton’s partnership with world-leading automotive tier 1 supplier, Koito,…
-
MissionIRNewsBreaks – Knightscope Inc. (NASDAQ: KSCP) Robot Show Takes the Spotlight in Houston, Texas
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced that its Robot Roadshow will land at EastGroup Properties, 3955 World Houston Pkwy, in Houston, Texas, on Oct. 27, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations…
-
MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Approval of Second Clinical Trial Site for Phase 1 Study
QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has added Rutgers Cancer Institute of New Jersey (“RCINJ”) as a clinical trial site for its phase 1 CycloSam study. RCINJ has been approved to begin enrolling patients into the study, which…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Eco Wave Power Global AB (NASDAQ: WAVE) Reports March 2026 Production Results from Jaffa Pilot Project
- MissionIRNewsBreaks – Megan Holdings Limited (NASDAQ: MGN) Closes $8.3 Million Follow-On Public Offering
- Beeline Holdings Inc. (NASDAQ: BLNE) Q4 Revenue Surge Portends 2026 Growth
- MissionIRNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Engages IBN for Corporate Communications Strategy
- MissionIRNewsBreaks – Micropolis AI Robotics (NYSE: MCRP) to Participate in Maxim Group AI Infrastructure Virtual Conference